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It has been established that e-aminocaproic acid (EACA) inhibits the activation of human plasminogen
(Ablondi et al., 1959; Alkjaersig,
Fletcher, and Sherry, 1959). Because
of this observation, this compound has
been used extensively to inhibit the
pathologically occurring fibrinolytic
system in patients. Recently Roberts
(1965) reported that another compound,
y-guanidinobutyric
acid
(GGBA), like EACA, inhibits the
Iysis of human blood clots. Furthermore, GGBA, unlike EACA, retards
the formation of these clots.
The present investigation was undertaken to determine whether GGBA
inhibits clot formation in the onestage prothrombin and in the partial
thromboplastin time tests. In addition,
the ability of GGBA to inhibit clot
lysis was tested using blood from a
patient showing active fibrinolysis.

Materials and Methods

Blood was collected in a 3.8% sodium citrate anticoagulant (9 parts
blood, 1 part citrate) from 15 individuals. The blood was centrifuged at
2,500 rpm in an angle centrifuge for
10 minutes to obtain the plasma. Clotting tests were performed in duplicate
in glass test tubes (10 X 75 mm. at
37° C. Solutions of EACA (Mann Research Laboratories, New York, N.Y.)
and GGBA (Calbiochem, Los Angeles,
Calif.) were prepared, each having a
concentration of 0.1 M in physiological saline. The pH of the EACA solution was 7.02 and that of the GGBA
solution was 7.03.
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The clotting tests were performed
in the following manner.
1. One-stage prothrombin time: 0.1
ml of plasma; 0.1 ml of either physiological saline (control), 0.1 M EACA,
or 0.1 M GGBA; 0.2 ml of equal
volumes of thromboplastin and CaCl2
(0.025 M). The time taken for clot
formation was measured.
2. Partial thromboplastin time: 0.1
ml of plasma; 0.1 ml of either physiological saline (control), 0.1 M EACA,
or 0.1 M GGBA; 0.1 ml of Thrombofax (Ortho Research Foundation, Raritan, N.J.). The mixture was incubated
for 30 seconds, and then 0.1 ml of
CaCI2 (0.025 M) was added. The tubes
were removed from the water bath after incubation for 60 seconds, wiped
dry, tilted, and the time taken for clot
formation was measured.
The euglobulin lysis time was performed as outlined by von Kaulla and
Schultz (1958), except that 0.1 ml of
either physiological saline, 0.1 M
EACA, or 0.1 M GGBA was added
to the euglobulin precipitate.
Results and Discussion

The effects of EACA and GGBA
on the clotting systems are shown in
table 1.
There was no significant difference
between the values obtained with the
one-stage test for the samples containing saline or EACA. The values obtained when GGBA was added, however, were significantly prolonged (p
< 0.001) when compared with the saline
control.
The findings for the partial thromboplastin test were similar to those
obtained for the one-stage test. GGBA
significantly prolonged the clotting
time when compared with the samples
containing either saline or EACA (p
< 0.01).

Opportunity to test the usefulness
of GGBA in a clinical situation presented itself when a 23-year-old Negro female, gravida 5 , para 3, abortus
1, delivered unattended at home a
stillborn term infant. Vaginal bleeding
was profuse, and a physician w as
called. When the latter noted that the
blood failed to clot, the patient was
transferred to the Medical College of
Virginia Hospital, arriving in a state
of shock. Numerous blood samples
were drawn and the clots lysed spontaneously within J;2 hour even though
considerable fresh blood and fibrinogen were administered. Following the
demonstration of a lytic process,
BACA was given intravenously and
an almost immediate cessation of the
lysis occurred. The results of euglobulin lysis times performed on the
plasma samples obtained prior to and
after the administration of BACA
(table 2) show that GGBA was effective in inhibiting lysis, but to a lesser
·.degree than was BACA.
GGBA is a naturally occurring
compound (Pisano, Abraham, and
Udenfriend, 1963) of low toxicity
(Kamiya, Kiyota, and Kita, 1962).
We have shown here that it, like
BACA, can inhibit the lysis of a clot
made from the plasma of a patient
with pathological fibrinolytic activity.
Therefore, it appears that GGBA, like
BACA, interferes with the activation
of human plasminogen by the naturally occurring activator. This work
also confirms that GGBA inhibits the
formation of clots when it is added to
normal plasma in the one-stage prothrombin or the partial thromboplastin time tests, while BACA has no
effect.
The mechanism of action of GGBA
in the formation and lysis of blood
clots is unknown.

TABLE 1

Effect EACA and GGBA on the One-Stage Prothrombin and Partial
Thromboplastin Times

No . of Samples

One-Stage
Prothrombin Time

Partial Thromboplastin Time

Mean

S.D. *

Mean

0.7
0.7
1.0

76
76
89

I

* S.D .

15
15
15

12.8
13.2
16.0

I

S.D. *

sec

sec

Saline control . .... . . ..
EACA , 0 .1 M . ... .. .. . .
GGBA , 0 .1 M .

I

5
6
14

standard deviation .

Summary

The addition of y-guanidinobutyric
acid (GGBA) to human plasma significantly prolonged the one-stage prothrombin and the partial thromboplastin times. On the other hand, the
addition of e-aminocaproic acid
(BACA) had no significant effect on
either of these tests. GGBA inhibited
the lysis of a clot that was formed
from the euglobulin fraction of the
blood of an obstetrical patient with
active fibrinolysis. BACA inhibited the
lysis to a lesser degree.
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